A 5-year multicentre randomized controlled trial comparing personalized, frozen and fresh blastocyst transfer in IVF.

Endometrial receptivity Endometrial receptivity analysis (ERA) Fresh embryo transfer (ET) Frozen embryo transfer (FET) Personalized embryo transfer (PET) Window of implantation (WOI)

Journal

Reproductive biomedicine online
ISSN: 1472-6491
Titre abrégé: Reprod Biomed Online
Pays: Netherlands
ID NLM: 101122473

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 10 04 2020
revised: 10 05 2020
accepted: 03 06 2020
pubmed: 30 7 2020
medline: 30 9 2021
entrez: 30 7 2020
Statut: ppublish

Résumé

Does clinical performance of personalized embryo transfer (PET) guided by endometrial receptivity analysis (ERA) differ from frozen embryo transfer (FET) or fresh embryo transfer in infertile patients undergoing IVF? Multicentre, open-label randomized controlled trial; 458 patients aged 37 years or younger undergoing IVF with blastocyst transfer at first appointment were randomized to PET guided by ERA, FET or fresh embryo transfer in 16 reproductive clinics. Clinical outcomes by intention-to-treat analysis were comparable, but cumulative pregnancy rate was significantly higher in the PET (93.6%) compared with FET (79.7%) (P = 0.0005) and fresh embryo transfer groups (80.7%) (P = 0.0013). Analysis per protocol demonstrates that live birth rates at first embryo transfer were 56.2% in PET versus 42.4% in FET (P = 0.09), and 45.7% in fresh embryo transfer groups (P = 0.17). Cumulative live birth rates after 12 months were 71.2% in PET versus 55.4% in FET (P = 0.04), and 48.9% in fresh embryo transfer (P = 0.003). Pregnancy rates at the first embryo transfer in PET, FET and fresh embryo transfer arms were 72.5% versus 54.3% (P = 0.01) and 58.5% (P = 0.05), respectively. Implantation rates at first embryo transfer were 57.3% versus 43.2% (P = 0.03), and 38.6% (P = 0.004), respectively. Obstetrical outcomes, type of delivery and neonatal outcomes were similar in all groups. Despite 50% of patients dropping out compared with 30% initially planned, per protocol analysis demonstrates statistically significant improvement in pregnancy, implantation and cumulative live birth rates in PET compared with FET and fresh embryo transfer arms, indicating the potential utility of PET guided by the ERA test at the first appointment.

Identifiants

pubmed: 32723696
pii: S1472-6483(20)30319-9
doi: 10.1016/j.rbmo.2020.06.002
pii:
doi:

Types de publication

Comparative Study Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

402-415

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Carlos Simón (C)

Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Valencia 46010, Spain; Igenomix Foundation-INCLIVA, Parque Tecnológico de Paterna, Ronda Narciso Monturiol Estarriol 11B, Paterna Valencia 46980, Spain; IVI-RMA Valencia, Plaza de la Policía Local 3, Valencia 46015, Spain. Electronic address: carlos.simon@uv.es.

Carlos Gómez (C)

Igenomix SL, Parque Tecnológico de Paterna, Ronda Narciso Monturiol Estarriol 11B, Paterna Valencia 46980, Spain.

Sergio Cabanillas (S)

IVI-RMA Valencia, Plaza de la Policía Local 3, Valencia 46015, Spain.

Iavor Vladimirov (I)

SBALAGRM-Sofia, 5 Baku St, Sofia 1756, Bulgaria.

Gemma Castillón (G)

IVI-RMA Barcelona, Ronda General Mitre 14 Barcelona 08017, Spain.

Juan Giles (J)

IVI-RMA Valencia, Plaza de la Policía Local 3, Valencia 46015, Spain.

Kubra Boynukalin (K)

Bahçeci Health Group-Fulya IVF Centre, Hakki Yeten Cad, 11 Kat 3, Terrace Fulya Istanbul 34365, Turkey.

Necati Findikli (N)

Bahçeci Health Group-Fulya IVF Centre, Hakki Yeten Cad, 11 Kat 3, Terrace Fulya Istanbul 34365, Turkey.

Mustafa Bahçeci (M)

Bahçeci Health Group-Fulya IVF Centre, Hakki Yeten Cad, 11 Kat 3, Terrace Fulya Istanbul 34365, Turkey.

Israel Ortega (I)

IVI-RMA Madrid, Av Del Talgo 68, Aravaca Madrid 28023, Spain.

Carmina Vidal (C)

IVI-RMA Valencia, Plaza de la Policía Local 3, Valencia 46015, Spain.

Miyako Funabiki (M)

Oak Clinic Japan, 2-7-9 Tamade-Nishi, Nishinari-ku Osaka 557-0045, Japan.

Alexandra Izquierdo (A)

ProcreaTec, Calle Manuel de Falla 6-8, Madrid 28036, Spain.

Lourdes López (L)

ProcreaTec, Calle Manuel de Falla 6-8, Madrid 28036, Spain.

Susana Portela (S)

IVI-RMA Vigo, Plaza Francisco Fernández del Riego 7, Vigo 36203, Spain.

Nilo Frantz (N)

Nilo Frantz Reproductive Medicine, Av Dr Nilo Peçanha 1221 - 10° andar, Boa Vista Porto Alegre, Brazil.

Marcos Kulmann (M)

Nilo Frantz Reproductive Medicine, Av Dr Nilo Peçanha 1221 - 10° andar, Boa Vista Porto Alegre, Brazil.

Sagiri Taguchi (S)

Oak Clinic Japan, 2-7-9 Tamade-Nishi, Nishinari-ku Osaka 557-0045, Japan.

Elena Labarta (E)

IVI-RMA Valencia, Plaza de la Policía Local 3, Valencia 46015, Spain.

Francisco Colucci (F)

Centro de Infertilidade e Medicina Fetal do Norte Fluminense, R Barão da Lagoa Dourada 409 - Centro, Campos dos Goytacazes Rio de Janeiro 28035-210, Brazil.

Shari Mackens (S)

Department of Reproductive Medicine, Universitair Ziekenhuis Brussel, 101 Laarbeeklaan, Jette Brussels 1090, Belgium.

Xavier Santamaría (X)

IVI-RMA Barcelona, Ronda General Mitre 14 Barcelona 08017, Spain.

Elkin Muñoz (E)

IVI-RMA Vigo, Plaza Francisco Fernández del Riego 7, Vigo 36203, Spain.

Saúl Barrera (S)

IVI-RMA Panama, Calle 50 & Calle 57 Este, Panama City Panamá 07185.

Juan Antonio García-Velasco (JA)

IVI-RMA Madrid, Av Del Talgo 68, Aravaca Madrid 28023, Spain.

Manuel Fernández (M)

IVI-RMA Sevilla, Av República Argentina 58 Sevilla 41011, Spain; Departamento de Cirugía, Universidad de Sevilla, Avda. Sánchez Pizjuan S/N Sevilla 41009, Spain; Departamento de Biología Molecular e Ingeniería Bioquímica, Universidad Pablo de Olavide Sevilla 41013, Spain.

Marcos Ferrando (M)

IVI-RMA Bilbao, Leioa Paseo Landabarri 1Vizcaya 48940, Spain.

María Ruiz (M)

Igenomix SL, Parque Tecnológico de Paterna, Ronda Narciso Monturiol Estarriol 11B, Paterna Valencia 46980, Spain.

Ben W Mol (BW)

Department of Obstetrics and Gynaecology, Monash University, Monash Medical Centre, 246 Clayton Road, Clayton Victoria 3168, Australia.

Diana Valbuena (D)

Igenomix Foundation-INCLIVA, Parque Tecnológico de Paterna, Ronda Narciso Monturiol Estarriol 11B, Paterna Valencia 46980, Spain; Igenomix SL, Parque Tecnológico de Paterna, Ronda Narciso Monturiol Estarriol 11B, Paterna Valencia 46980, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH